Ascendis Total Revenue vs Cost Of Revenue Analysis

ASND Stock

USD 130.85 1.04 0.80%

Ascendis Pharma financial indicator trend analysis is way more than just evaluating Ascendis Pharma AS prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ascendis Pharma AS is a good investment. Please check the relationship between Ascendis Pharma Total Revenue and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Revenue vs Cost Of Revenue

Total Revenue vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ascendis Pharma AS Total Revenue account and Cost Of Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Ascendis Pharma's Total Revenue and Cost Of Revenue is -0.15. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Ascendis Pharma AS, assuming nothing else is changed. The correlation between historical values of Ascendis Pharma's Total Revenue and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Ascendis Pharma AS are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Total Revenue i.e., Ascendis Pharma's Total Revenue and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.15

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Revenue

Total revenue comprises all receipts Ascendis Pharma AS generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Cost Of Revenue

Cost of Revenue is found on Ascendis Pharma AS income statement and represents the costs associated with goods and services Ascendis Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Ascendis Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ascendis Pharma AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At present, Ascendis Pharma's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 7 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.92.

	2021	2022	2023	2024 (projected)
Interest Expense	3.9M	50.5M	44.1M	46.3M
Depreciation And Amortization	16.0M	17.6M	18.9M	19.9M

Interest Expense Depreciation And Amortization

Ascendis Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Common Stock Shares Outstanding	Net Tangible Assets
Total Assets		0.55	0.67	0.64	0.92	-0.69	-0.23	-0.8	0.73	0.91	0.93	0.87	0.97	0.28	-0.17	0.91	0.53	0.82	0.57	0.84	0.99	0.73	0.93	0.6	0.94	0.83
Short Long Term Debt Total	0.55		0.98	-0.26	0.77	-0.46	0.61	-0.92	0.94	0.4	0.4	0.8	0.44	0.9	-0.81	0.5	1.0	0.82	1.0	0.88	0.58	0.96	0.54	0.96	0.58	0.2
Total Current Liabilities	0.67	0.98		-0.1	0.86	-0.49	0.5	-0.97	0.98	0.5	0.54	0.88	0.56	0.85	-0.76	0.6	0.97	0.91	0.98	0.94	0.69	0.99	0.64	0.96	0.68	0.35
Total Stockholder Equity	0.64	-0.26	-0.1		0.39	-0.43	-0.85	-0.11	0.0	0.71	0.72	0.32	0.73	-0.44	0.41	0.56	-0.29	0.22	-0.24	0.2	0.6	-0.02	0.57	-0.12	0.55	0.85
Property Plant And Equipment Net	0.92	0.77	0.86	0.39		-0.61	0.09	-0.93	0.87	0.76	0.88	0.91	0.85	0.55	-0.48	0.76	0.75	0.92	0.78	0.98	0.9	0.9	0.81	0.81	0.83	0.72
Current Deferred Revenue	-0.69	-0.46	-0.49	-0.43	-0.61		0.24	0.57	-0.59	-0.78	-0.53	-0.71	-0.73	-0.33	0.3	-0.82	-0.44	-0.58	-0.46	-0.58	-0.72	-0.53	-0.84	-0.54	-0.82	-0.66
Net Debt	-0.23	0.61	0.5	-0.85	0.09	0.24		-0.32	0.41	-0.47	-0.27	0.06	-0.39	0.66	-0.6	-0.28	0.64	0.26	0.61	0.27	-0.21	0.44	-0.26	0.48	-0.22	-0.58
Retained Earnings	-0.8	-0.92	-0.97	-0.11	-0.93	0.57	-0.32		-0.96	-0.66	-0.7	-0.94	-0.71	-0.77	0.68	-0.73	-0.9	-0.94	-0.92	-0.98	-0.81	-0.97	-0.77	-0.94	-0.8	-0.54
Accounts Payable	0.73	0.94	0.98	0.0	0.87	-0.59	0.41	-0.96		0.57	0.58	0.9	0.64	0.77	-0.67	0.68	0.94	0.94	0.95	0.94	0.76	0.98	0.73	0.91	0.76	0.4
Cash	0.91	0.4	0.5	0.71	0.76	-0.78	-0.47	-0.66	0.57		0.78	0.82	0.96	0.22	-0.14	0.92	0.37	0.62	0.41	0.66	0.92	0.56	0.93	0.5	0.93	0.88
Non Current Assets Total	0.93	0.4	0.54	0.72	0.88	-0.53	-0.27	-0.7	0.58	0.78		0.74	0.88	0.16	-0.11	0.76	0.37	0.76	0.42	0.78	0.88	0.61	0.78	0.5	0.79	0.87
Non Currrent Assets Other	0.87	0.8	0.88	0.32	0.91	-0.71	0.06	-0.94	0.9	0.82	0.74		0.83	0.65	-0.58	0.84	0.78	0.91	0.81	0.92	0.88	0.89	0.88	0.87	0.91	0.7
Cash And Short Term Investments	0.97	0.44	0.56	0.73	0.85	-0.73	-0.39	-0.71	0.64	0.96	0.88	0.83		0.17	-0.1	0.89	0.42	0.73	0.45	0.74	0.97	0.63	0.92	0.5	0.93	0.87
Net Receivables	0.28	0.9	0.85	-0.44	0.55	-0.33	0.66	-0.77	0.77	0.22	0.16	0.65	0.17		-0.94	0.32	0.9	0.61	0.89	0.7	0.31	0.8	0.34	0.92	0.38	0.08
Good Will	-0.17	-0.81	-0.76	0.41	-0.48	0.3	-0.6	0.68	-0.67	-0.14	-0.11	-0.58	-0.1	-0.94		-0.17	-0.8	-0.53	-0.79	-0.62	-0.18	-0.7	-0.23	-0.85	-0.26	-0.1
Common Stock Total Equity	0.91	0.5	0.6	0.56	0.76	-0.82	-0.28	-0.73	0.68	0.92	0.76	0.84	0.89	0.32	-0.17		0.48	0.72	0.51	0.71	0.93	0.63	0.99	0.58	0.98	0.77
Non Current Liabilities Total	0.53	1.0	0.97	-0.29	0.75	-0.44	0.64	-0.9	0.94	0.37	0.37	0.78	0.42	0.9	-0.8	0.48		0.81	1.0	0.86	0.56	0.95	0.53	0.94	0.56	0.16
Other Current Assets	0.82	0.82	0.91	0.22	0.92	-0.58	0.26	-0.94	0.94	0.62	0.76	0.91	0.73	0.61	-0.53	0.72	0.81		0.83	0.95	0.82	0.93	0.78	0.83	0.81	0.56
Total Liab	0.57	1.0	0.98	-0.24	0.78	-0.46	0.61	-0.92	0.95	0.41	0.42	0.81	0.45	0.89	-0.79	0.51	1.0	0.83		0.88	0.59	0.97	0.55	0.95	0.59	0.21
Property Plant And Equipment Gross	0.84	0.88	0.94	0.2	0.98	-0.58	0.27	-0.98	0.94	0.66	0.78	0.92	0.74	0.7	-0.62	0.71	0.86	0.95	0.88		0.84	0.97	0.76	0.9	0.79	0.6
Total Current Assets	0.99	0.58	0.69	0.6	0.9	-0.72	-0.21	-0.81	0.76	0.92	0.88	0.88	0.97	0.31	-0.18	0.93	0.56	0.82	0.59	0.84		0.75	0.95	0.62	0.96	0.8
Short Term Debt	0.73	0.96	0.99	-0.02	0.9	-0.53	0.44	-0.97	0.98	0.56	0.61	0.89	0.63	0.8	-0.7	0.63	0.95	0.93	0.97	0.97	0.75		0.68	0.94	0.71	0.4
Common Stock	0.93	0.54	0.64	0.57	0.81	-0.84	-0.26	-0.77	0.73	0.93	0.78	0.88	0.92	0.34	-0.23	0.99	0.53	0.78	0.55	0.76	0.95	0.68		0.62	1.0	0.8
Other Current Liab	0.6	0.96	0.96	-0.12	0.81	-0.54	0.48	-0.94	0.91	0.5	0.5	0.87	0.5	0.92	-0.85	0.58	0.94	0.83	0.95	0.9	0.62	0.94	0.62		0.65	0.38
Common Stock Shares Outstanding	0.94	0.58	0.68	0.55	0.83	-0.82	-0.22	-0.8	0.76	0.93	0.79	0.91	0.93	0.38	-0.26	0.98	0.56	0.81	0.59	0.79	0.96	0.71	1.0	0.65		0.79
Net Tangible Assets	0.83	0.2	0.35	0.85	0.72	-0.66	-0.58	-0.54	0.4	0.88	0.87	0.7	0.87	0.08	-0.1	0.77	0.16	0.56	0.21	0.6	0.8	0.4	0.8	0.38	0.79

Click cells to compare fundamentals

Ascendis Pharma Account Relationship Matchups

Ascendis Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	676.7M	979.8M	1.1B	1.1B	825.6M	477.4M
Short Long Term Debt Total	36.6M	92.0M	105.0M	508.4M	644.3M	676.5M
Total Current Liabilities	48.0M	52.8M	100.4M	171.3M	197.3M	207.2M
Total Stockholder Equity	597.1M	838.7M	883.6M	263.3M	(145.7M)	(138.4M)
Property Plant And Equipment Net	45.1M	108.1M	126.0M	129.1M	110.6M	116.2M
Current Deferred Revenue	858K	363K	2.6M	1.2M	1.1M	1.0M
Net Debt	(561.5M)	(492.5M)	(341.3M)	63.6M	252.1M	264.7M
Retained Earnings	(611.3M)	(1.0B)	(1.4B)	(1.9B)	(2.3B)	(2.2B)
Accounts Payable	27.8M	21.9M	59.4M	101.0M	94.6M	99.3M
Cash	598.1M	584.5M	446.3M	444.8M	392.2M	282.5M
Non Current Assets Total	65.6M	239.7M	279.0M	166.3M	122.9M	79.4M
Non Currrent Assets Other	1.5M	1.4M	1.8M	1.9M	2.1M	2.2M
Cash And Short Term Investments	598.1M	718.8M	682.1M	735.5M	399.4M	339.0M
Net Receivables	5.4M	387K	2.2M	11.9M	55.8M	58.6M
Common Stock Total Equity	5.0M	5.7M	6.4M	7.2M	8.3M	4.2M
Liabilities And Stockholders Equity	676.7M	979.8M	1.1B	1.1B	825.6M	477.4M
Non Current Liabilities Total	31.6M	88.3M	100.9M	655.1M	773.9M	812.6M
Other Current Assets	7.6M	14.0M	46.2M	45.4M	38.6M	40.5M
Total Liab	79.6M	141.1M	201.3M	826.4M	971.3M	1.0B
Property Plant And Equipment Gross	45.1M	108.1M	160.0M	175.7M	182.2M	191.3M
Total Current Assets	611.2M	740.1M	805.9M	923.5M	702.7M	398.0M
Accumulated Other Comprehensive Income	590.7M	831.5M	876.0M	255.7M	(153.4M)	(145.8M)
Short Term Debt	5.9M	6.9M	14.0M	25.4M	25.4M	26.7M
Common Stock	6.4M	7.2M	7.6M	7.7M	7.7M	5.2M
Other Current Liab	13.5M	23.7M	26.8M	39.3M	75.1M	78.8M
Common Stock Shares Outstanding	46.5M	50.6M	54.8M	56.1M	56.3M	39.2M
Net Tangible Assets	593.6M	833.0M	878.4M	258.5M	297.3M	374.1M
Other Assets	1.5M	1.4M	1.8M	1.9M	2.2M	2.3M
Other Stockholder Equity	611.3M	698.5M	872.2M	252.2M	2.3B	2.4B
Property Plant Equipment	45.1M	108.1M	126.0M	129.1M	148.5M	155.9M
Other Liab	908K	3.2M	3.0M	172.2M	198.0M	207.9M
Capital Lease Obligations	36.6M	92.0M	105.0M	109.2M	98.8M	103.7M
Inventory	(3.0)	1.0	75.4M	130.7M	208.9M	219.4M
Long Term Investments	15.5M	124.5M	145.9M	30.4M	5.7M	5.4M
Intangible Assets	4.4M	2.2M	1.8M	1.3M	924K	877.8K
Net Invested Capital	597.1M	838.7M	883.6M	771.7M	399.8M	622.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:

How To Invest In Ascendis

Details

Is Ascendis Stock a good investment?

Details

What is Ascendis Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.81)

Revenue Per Share

5.595

Quarterly Revenue Growth

(0.24)

Return On Assets

(0.28)

Return On Equity

(8.18)

The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ascendis Total Revenue vs Cost Of Revenue Analysis

Total Revenue vs Cost Of Revenue

Total Revenue vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Total Revenue

Cost Of Revenue

Ascendis Pharma fundamental ratios Correlations

Ascendis Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ascendis Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock Shares Outstanding	+ 1.0	Common Stock
Total Current Assets	+ 0.99	Total Assets
Short Term Debt	+ 0.99	Total Current Liabilities

Property Plant And Equipment Gross	- 0.98	Retained Earnings
Short Term Debt	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Accounts Payable	- 0.96	Retained Earnings
Good Will	- 0.94	Net Receivables
Other Current Liab	- 0.94	Retained Earnings